Adjuvant NY-ESO-1 Vaccine Immunotherapy in High-risk Resected Melanoma: a Retrospective Cohort Analysis

Overview

Journal J Immunother Cancer

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2018 May 19

PMID 29773080

Citations 8

Authors

Michael Lattanzi

Joseph Han

Una Moran

Kierstin Utter

Jeremy Tchack

Rachel Lubong Sabado

Russell Berman

Richard Shapiro

Hsin-Hui Huang

Iman Osman

Nina Bhardwaj

Anna C Pavlick

Affiliations

Soon will be listed here.

Abstract

Background: Cancer-testis antigen NY-ESO-1 is a highly immunogenic melanoma antigen which has been incorporated into adjuvant vaccine clinical trials. Three such early-phase trials were conducted at our center among patients with high-risk resected melanoma. We herein report on the pooled long-term survival outcomes of these patients in comparison to historical controls.

Methods: All melanoma patients treated at NYU Langone Health under any of three prospective adjuvant NY-ESO-1 vaccine trials were retrospectively pooled into a single cohort. All such patients with stage III melanoma were subsequently compared to historical control patients identified via a prospective institutional database with protocol-driven follow-up. Survival times were calculated using the Kaplan-Meier method, and Cox proportional hazard models were employed to identify significant prognostic factors and control for confounding variables.

Results: A total of 91 patients were treated with an NY-ESO-1 vaccine for the treatment of high-risk resected melanoma. Of this group, 67 patients were stage III and were selected for comparative analysis with 123 historical control patients with resected stage III melanoma who received no adjuvant therapy. Among the pooled vaccine cohort (median follow-up 61 months), the estimated median recurrence-free survival was 45 months, while the median overall survival was not yet reached. In the control cohort of 123 patients (median follow-up 30 months), the estimated median recurrence-free and overall survival were 22 and 58 months, respectively. Within the retrospective stage III cohort, NY-ESO-1 vaccine was associated with decreased risk of recurrence (HR = 0.56, p < 0.01) and death (HR = 0.51, p = 0.01). Upon controlling for sub-stage, the adjuvant NY-ESO-1 clinical trial cohort continued to exhibit decreased risk of recurrence (HR = 0.45, p < 0.01) and death (HR = 0.40, p < 0.01).

Conclusions: In this small retrospective cohort of resected stage III melanoma patients, adjuvant NY-ESO-1 vaccine immunotherapy was associated with longer recurrence-free and overall survival relative to historical controls. These data support the continued investigation of adjuvant NY-ESO-1 based immunotherapy regimens in melanoma.

Citing Articles

[Current vaccination and immunization strategies in dermatology].

Schrenker S, Erpenbeck L Dermatologie (Heidelb). 2024; 75(11):889-901.

PMID: 39352489 DOI: 10.1007/s00105-024-05400-0.

Identification of pan-cancer/testis genes and validation of therapeutic targeting in triple-negative breast cancer: Lin28a-based and Siglece-based vaccination induces antitumor immunity and inhibits metastasis.

Carter J, Matta B, Battaglia J, Somerville C, Harris B, Lapan M J Immunother Cancer. 2023; 11(12).

PMID: 38135347 DOI: 10.1136/jitc-2023-007935.

Cell-Sized Lipid Vesicles as Artificial Antigen-Presenting Cells for Antigen-Specific T Cell Activation.

Chen J, Agrawal S, Yi H, Vallejo D, Agrawal A, Lee A Adv Healthc Mater. 2023; 12(12):e2203163.

PMID: 36645182 PMC: 10175210. DOI: 10.1002/adhm.202203163.

Recurrence Patterns for Regionally Metastatic Melanoma Treated in the Era of Adjuvant Therapy: A Systematic Review and Meta-Analysis.

Perez-Morales J, Broman K, Bettampadi D, Haver M, Zager J, Schabath M Ann Surg Oncol. 2022; 30(4):2364-2374.

PMID: 36479663 DOI: 10.1245/s10434-022-12866-6.

Vaccines for immunoprevention of cancer.

Enokida T, Moreira A, Bhardwaj N J Clin Invest. 2021; 131(9).

PMID: 33938446 PMC: 8087198. DOI: 10.1172/JCI146956.

References

Scheibenbogen C, Schmittel A, Keilholz U, Allgauer T, Hofmann U, Max R . Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother. 2000; 23(2):275-81. DOI: 10.1097/00002371-200003000-00012. View

Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A . Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A. 2012; 109(15):5797-802. PMC: 3326498. DOI: 10.1073/pnas.1117208109. View

Simpson A, Caballero O, Jungbluth A, Chen Y, Old L . Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005; 5(8):615-25. DOI: 10.1038/nrc1669. View

Jager E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D . Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A. 2006; 103(39):14453-8. PMC: 1570182. DOI: 10.1073/pnas.0606512103. View

Vantomme V, Dantinne C, Amrani N, Permanne P, Gheysen D, Bruck C . Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother. 2004; 27(2):124-35. DOI: 10.1097/00002371-200403000-00006. View

Jager E, Gnjatic S, Nagata Y, STOCKERT E, Jager D, Karbach J . Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A. 2000; 97(22):12198-203. PMC: 17318. DOI: 10.1073/pnas.220413497. View

Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G, Marty V . Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res. 1999; 5(10):2756-65. View

Ott P, Hodi F . Talimogene Laherparepvec for the Treatment of Advanced Melanoma. Clin Cancer Res. 2016; 22(13):3127-31. DOI: 10.1158/1078-0432.CCR-15-2709. View

Andtbacka R, Kaufman H, Collichio F, Amatruda T, Senzer N, Chesney J . Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33(25):2780-8. DOI: 10.1200/JCO.2014.58.3377. View

10.

Davis I, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W . Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A. 2004; 101(29):10697-702. PMC: 489997. DOI: 10.1073/pnas.0403572101. View

11.

Klein O, Davis I, McArthur G, Chen L, Haydon A, Parente P . Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma. Cancer Immunol Immunother. 2015; 64(4):507-18. PMC: 11029160. DOI: 10.1007/s00262-015-1656-x. View

12.

Robbins P, Morgan R, Feldman S, Yang J, Sherry R, Dudley M . Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011; 29(7):917-24. PMC: 3068063. DOI: 10.1200/JCO.2010.32.2537. View

13.

Bender A, Karbach J, Neumann A, Jager D, Al-Batran S, Atmaca A . LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immun. 2007; 7:16. PMC: 2935748. View

14.

Schwartzentruber D, Lawson D, Richards J, Conry R, Miller D, Treisman J . gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011; 364(22):2119-27. PMC: 3517182. DOI: 10.1056/NEJMoa1012863. View

15.

Nicholaou T, Chen W, Davis I, Jackson H, Dimopoulos N, Barrow C . Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™. Cancer Immunol Immunother. 2011; 60(11):1625-37. PMC: 11028944. DOI: 10.1007/s00262-011-1041-3. View

16.

Sondak V, Sosman J . Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. Semin Cancer Biol. 2004; 13(6):409-15. DOI: 10.1016/j.semcancer.2003.09.004. View

17.

Fossa A, Berner A, Fossa S, Hernes E, Gaudernack G, Smeland E . NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate. 2004; 59(4):440-7. DOI: 10.1002/pros.20025. View

18.

Filipazzi P, Pilla L, Mariani L, Patuzzo R, Castelli C, Camisaschi C . Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Clin Cancer Res. 2012; 18(23):6485-96. DOI: 10.1158/1078-0432.CCR-12-1516. View

19.

Jungbluth A, Antonescu C, Busam K, Iversen K, Kolb D, Coplan K . Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer. 2001; 94(2):252-6. DOI: 10.1002/ijc.1451. View

20.

Rubin J, Day R, Duquesnoy R, Simonis B, Adams S, Lee J . HLA-DQ1 is associated with clinical response and survival of patients with melanoma who are treated with interleukin-2. Ther Immunol. 1995; 2(1):1-6. View